Astellas Announces Acquisition of Quethera's Ophthalmic Gene Therapy Program
Shots:
- The agreement involves Astellas to pay an upfront payment of £85Mn to Quethera’s shareholder’s
- Quethera uses recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells to treat glaucoma
- In pre-clinical models- this gene therapy improved survival rates of retinal ganglion cells (RGCs) in pre-clinical models
Ref: Astellas | Image: Astellas
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com